LCM
BCRX icon

Laurion Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Laurion Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-148,655
Closed -$919K – 315
2024
Q2 		$919K Buy
148,655
+26,218
+21% +$145K 0.01% 300
2024
Q1 		$622K Sell
122,437
-11,338
-8% -$63.8K 0.01% 419
2023
Q4 		$801K Buy
+133,775
New +$775K 0.01% 360
2017
Q4 		– Sell
-216,162
Closed -$1.13M – 1529
2017
Q3 		$1.13M Buy
+216,162
New +$1.11M 0.01% 933

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Laurion Capital Management's BCRX Position: Q3 2024 in Review

Laurion Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2024, closing a stake of 148,655 shares — an estimated $919K sold.

Laurion Capital Management first reported a position in BCRX in Q3 2017 and held it in 4 quarters. The position peaked at $1.13M in Q3 2017. 257 funds tracked by Wall St. Rank hold BCRX as of Q3 2024.

  • Laurion Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Laurion Capital Management sold 148,655 BioCryst Pharmaceuticals shares in Q3 2024, an estimated $919K.
  • Laurion Capital Management first reported a position in BioCryst Pharmaceuticals in Q3 2017 and held it in 4 quarters.
  • Laurion Capital Management's BioCryst Pharmaceuticals position peaked at $1.13M in Q3 2017.
  • 257 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2024.

Based on Laurion Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.